Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06885385 | A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer | PHASE2 | RECRUITING | 60 | — | — | Apr 23, 2025 | Feb 13, 2027 | Jun 24, 2025 | 2 | China |
Incidence and severity of DLT
Adverse events (AE), Abnormal changes in laboratory and other tests with clinical significance
Recommended dose for phase II trial
Defined as the proportion of subjects who achieved partial response (PR) or complete response (CR)
| Arm | Type | Description |
|---|---|---|
| JS207 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JS207 | BIOLOGICAL | JS207 will be administered every 3 weeks for a treatment cycle of 21 days |
| JS015 | BIOLOGICAL | JS015 will be administered every 3 weeks for a treatment cycle of 21 days |
| Capecitabine | DRUG | Capecitabine of 1000mg/m2 will be administered orally twice daily from day 1 to 14 every 21 day cycle |
| Oxaliplatin | DRUG | Oxaliplatin of 130mg/m2 will be administered intravenously (IV) on day 1 every 21 day cycle |
Inclusion Criteria: 1. Subjects aged 18 to 75 (inclusive) at the time of signing the consent form, both male and female 2. Colorectal adenocarcinoma or rectal adenocarcinoma with histological or cytological Qualification, according to the 8th edition of the AJCC colorectal cancer TNM staging stage ...